Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F)(the “Company” or “Isodiol”), a global bio-active phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that it has signed a binding agreement with Namaste Technologies Inc. (“Namaste”) (CNSX:N) (OTCQB:NXTTF) (FRA:M5BQ), an online retailer for cannabis delivery systems globally. Through this non-exclusive partnership, Isodiol will become a provider of phytoceutical products to Namaste, to be sold through select distribution channels on its e-commerce platform.
“The shopping habits of today’s consumers are greatly steered towards e-commerce and we want our customers to have the same convenience and ease when shopping for cannabinoid products that they do with other items,” said Marcos Agramont, CEO of Isodiol. “This partnership will be a great compliment to our current e-commerce platform as Namaste has expansive international distribution channels that will allow us to expand our product offerings on a global scale. We look forward to providing their consumers with safe, consistent and highly bio-active phytoceutical products.”
This agreement is mutually beneficial for both companies, as it offers a new domestic and international sales channel for Isodiol to distribute its products. In addition, this agreement adds significant value to Namaste’s product offering on a global scale and through its wholly owned subsidiary, Cannmart Inc. (“Cannmart”), which is an Access to Cannabis for Medical Purposes (“ACMPR”) applicant for a medical cannabis “sales-only” license. Namaste intends to offer Isodiol’s innovative pharmaceutical-grade products to Cannmart patients and to distribute the products in regional markets where cannabinoid products are available.
“This transaction further demonstrates our eagerness to attract industry leaders who see value and can benefit from our revolutionary e-commerce platform. We are very much looking forward to offering Isodiol’s best in-class quality range of products through our sales channels, as we look to broaden our product offerings to encompass some of the most innovative phytoceutical products in the market,” said Sean Dollinger, President and CEO of Namaste. “Namaste remains focused on becoming a global leader in the cannabis space. We are extremely confident in our model and believe amalgamating the industry’s most innovative products in one marketplace will revolutionize the cannabis industry. This partnership reaffirms the traction Namaste is gaining in the cannabis space, as our peers look to source out innovative platforms to distribute their products and grow their market share. We are extremely pleased to have partnered with Isodiol and look forward to launching their products through our marketplace in the near future.”
For more information on Isodiol, please visit www.isodiol.com
For more information on Namaste, please visit www2.namastetechnologies.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bio-active pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.
Join Us On Facebook: https://www.facebook.com/isodiol/
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
North 6th Agency
ON BEHALF OF THE BOARD OR NAMASTE TECHNOLOGIES INC.
Sean Dollinger, President and CEO
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.
Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry
Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.
Nextleaf Solutions Provides a Corporate Update and Comments on Financial Results from the First Quarter
Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:
Nextleaf Comments on Financial Results from Q1 Financials
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.
The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.
FinCanna Capital – The Only Publicly Traded, Royalty-Focused Company for the Licensed U.S. Cannabis Industry Provides Corporate Update
Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues
FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million
Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.